🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Barclays bullish on Waystar with overweight rating, $24 target

EditorLina Guerrero
Published 07/02/2024, 02:55 PM
WAY
-

On Tuesday, Barclays began coverage on Waystar Holding (NASDAQ:WAY), assigning an Overweight rating and setting a price target of $24.00. Waystar, recognized as a leader in clearinghouse, patient payments, and revenue cycle technology, offers solutions that expedite payments for providers. This service is particularly valuable in a market known for its extremely narrow margins, which have been further compressed since the pandemic.

The firm's assessment highlights Waystar's business model, which delivers consistent low double-digit revenue growth and impressive EBITDA margins around 40%. Additionally, Waystar's financial strategy includes a natural de-levering process. These factors, according to Barclays, should set Waystar apart from its peers in the health tech sector and justify a higher market multiple. The current valuation, however, only partially reflects this premium, supporting the Overweight rating.

Waystar's alignment with essential health tech markets is seen as a shield against the typical volatility of the sector. The company's robust business model is expected to attract a premium multiple due to its uncommon durability in the health tech industry. Barclays anticipates that Waystar's focused end markets will continue to experience high single-digit transaction volume growth and low double-digit growth in revenue potential, providing a solid foundation for the company's overall growth.

The analyst firm believes that the increasing complexity of healthcare payments will further bolster Waystar's position in the market. The company's ability to navigate this complexity is seen as a key advantage, ensuring sustained transaction volume and revenue growth in the foreseeable future.

InvestingPro Insights

Waystar Holding's recent performance and market position can be further illuminated by reviewing the latest data and insights from InvestingPro. With a market capitalization of $3.6 billion, Waystar is a significant player in the health tech sector. Despite analysts' concerns that the company may not achieve profitability this year, the firm has demonstrated robust revenue growth, with a 13.98% increase over the last twelve months as of Q1 2024. This is complemented by an even more impressive quarterly revenue growth rate of 17.64%.

InvestingPro Tips suggest that Waystar is trading near its 52-week high, with the price reaching 93.63% of this peak, indicating a strong market confidence in the stock. Additionally, the company's gross profit margin stands at an impressive 67.77%, underlining the efficiency of Waystar's business model. However, it's worth noting that the company's P/E ratio is currently negative at -64.46, reflecting the market's anticipation of future earnings potential rather than current profitability.

For those interested in further insights and analytics, there are additional InvestingPro Tips available, which can be explored through the dedicated InvestingPro platform. Investors can use the coupon code PRONEWS24 to receive up to 10% off a yearly Pro and a yearly or biyearly Pro+ subscription, unlocking even more valuable data to inform their investment decisions. With these insights, stakeholders can better gauge the potential risks and rewards associated with investing in Waystar Holding.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.